Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human
CSTI-500 is a potent monoamine TRI with substantial striatal SERT and moderate DAT occupancies in healthy subjects. Together with promising safety-tolerability and pharmacokinetics profiles, the continued clinical development of CSTI-500 is strongly supported.
Authors
- Harald Murck (ORCID: https://orcid.org/0000-0003-4827-1945)
- Gunnar Antoni (ORCID: https://orcid.org/0000-0002-1525-5255)
- Lieuwe Appel (ORCID: https://orcid.org/0009-0008-9933-4137)
- Shuang Liu (ORCID: https://orcid.org/0000-0002-2439-9330)
- Robert Risinger
- Anders Wall
- Roger Lane (ORCID: https://orcid.org/0009-0004-9301-6083)
Institutions
- Uppsala University (SE)
- Uppsala University Hospital (SE)
- Philipps University of Marburg (DE)
- Ionis Pharmaceuticals (United States) (US)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- Psychopharmacology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1007/s00213-025-06861-4
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Foundation for Prader-Willi Research
- Uppsala Universitet